Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Leucine-rich repeat, immunoglobulin-like and transmembrane domains 3 (LRIT3)
- Target
- LRIT3
- Molecular classification
- Other (single-pass transmembrane protein with leucine-rich repeat, immunoglobulin-like domain, and fibronectin type III domain)
01
Overview
Leucine-rich repeat, immunoglobulin-like and transmembrane domains 3 (LRIT3) is a single-pass transmembrane protein characterized by leucine-rich repeat, immunoglobulin-like, and fibronectin type III domains. It acts as a modulator of fibroblast growth factor receptor (FGFR) signaling, which is involved in craniofacial and skeletal development through pathways such as MAPK, PI3K/AKT, and PLC. While LRIT3’s precise physiological and disease associations are not comprehensively defined in the presented literature, its role as a regulator of FGFR positions it as a candidate molecule for modulatory functions in cellular signaling and development.
- Other names
- LRIT3Leucine-rich repeat, Ig-like and transmembrane domain-containing protein 3LRR immunoglobulin-like and transmembrane domains 3
02
Biological functions
Modulation of fibroblast growth factor receptor (FGFR) signalingSignal transduction
03
Disease associations
Other (modulation of FGFR signaling; specific diseases not clearly established in the provided sources)
Beyond the preview
Go deeper on Leucine-rich repeat, immunoglobulin-like and transmembrane domains 3 (LRIT3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Leucine-rich repeat, immunoglobulin-like and transmembrane domains 3 (LRIT3).